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Available online 3 March 2016Objectives: The objective of thepresent studywas to compare the long termoutcomes of balloon angioplasty (BA)
versus drug-eluting stents (DES) in bare-metal stent in-stent restenosis (BMS-ISR).
Background: Coronary in-stent restenosis (ISR) remains a signiﬁcant clinical problem. Long term results after
management of ISR may help improve treatment strategies.
Methods: We assessed 5-year clinical outcomes in cohort of 269 patients with BMS-ISR treated with DES (n =
154) and BA (n = 115) between June 2007 and January 2010 at our institution.
Results: Clinical and demographic characteristics were similar for both groups. Mehran classiﬁcation was used to
classify ISR lesions. BA were used predominantly in classes I and II, whereas classes III and IV were treated with
DES (p b 0.0001). Percentages of major adverse cardiovascular events (MACE) including death, myocardial in-
farction (MI) and target vessel revascularization (TVR) for 4.37 ± 1.1 years were 50.4% and 31.8% for the BA
and DES groups, respectively (p= 0.002). Although patients in the BA group had signiﬁcantly higher rates of re-
current angina (42.6% vs. 27.3%, p = 0.009) and TVR (37.4% vs. 20.8%, p = 0.003), MI (6.1% vs. 5.2%, p = 0.752)
and cardiac death (21.7% vs. 16.2%, p=0.251)were similar in both groups.MACE-free 1-year survival and 5-year
survival rates were signiﬁcantly higher in DES group compared to BA group (1 year survival: 91.6% vs. 71.3
p b 0.001, and 5 year survival: 68.2% vs. 49.6%, p b 0.0001, respectively).
Conclusions:AlthoughDESweremore frequently used in to treat complicated lesions in patientswith ISR, follow-
up MACE rates were signiﬁcantly lower and MACE-free survival was signiﬁcantly better in the DES treated
patients.
© 2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Development of bare metal stents (BMS) has become a major ad-
vancement in the treatment of coronary artery disease. BMS reduce re-
stenosis rates by attenuating arterial recoil and contraction as compared
to balloon angioplasty. However, in-stent restenosis (ISR) still occurs in
approximately 10–20% of cases.1 Despite high rates of restenosis, BMS
are widely used for treating coronary artery disease.2 Treatment of ISR
remains a major challenge for clinicians. There are many treatment op-
tions for patients having ISR like recurrent balloon angioplasty (BA),
drug-eluting stents (DES) or BMS, cutting balloon angioplasty, direc-
tional coronary atherectomy, rotational coronary atherectomy and vas-
cular brachytherapy.3–6 Although vascular brachytherapy is an effectivediovascular Academy.
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my. Production and hosting by Elsetreatment of ISR, it requires additional personnel, training and equip-
ment. BA may be preferred in patients with contraindications for dual
antiplatelet therapy (DAPT). Weintraub et al. showed that restenosis
that developed following successful BA has no adverse effect on long-
term survival.7
In this study, we compared the long term results of new-generaton
DES with those of BA in patients presenting with BMS-ISR.
Material and methods
Patients
We analyzed clinical and angiographic data of patients who
underwent PCI in our institution between June 2007 and January
2010. A total of 398 patients developed BMS-ISR during the study peri-
od. Of the 398 patients, 88 hadDES-ISR, 11patients underwent coronary
artery bypass graft surgery, 9 patients underwent hybrid coronary re-
vascularization, 3 patients refused percutanous intervention, and 18 pa-
tients were lost to follow-up. The remaining 269 patients who were
treated with balloon angioplasy or DES enrolled in the study. Patientsvier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Patient and treatment group proﬁle. BMS ISR; bare metal in-stent restenosis, DES; drug eluting stent, DES ISR; drug eluting stent in-stent restenosis, ISR; instent restenosis.
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(154 patients). Fig. 1 shows diagram of patients included and excluded
in the study. Follow-up for all patients was continued until July 2013.
The study was approved by the local ethics committee.
Clinical and laboratory evaluation
A medical history was taken from each patient, followed by a phys-
ical examination. Patient data were extracted from electronic medical
records. The collected data included patient demographics, clinical
characteristics, risk factors (arterial hypertension, diabetes mellitus,
smoking, family history of coronary artery disease, dyslipidemia), med-
ications, previous invasive cardiac procedures and echocardiographic
ﬁndings including left ventricular ejection fraction (LVEF). Patients
were excluded if they had active infection, anemia, renal failure, hepatic
disease and thyroid function abnormalities. Patients received DAPT for
four weeks after BMS implantation. Coronary angiography was per-
formed to deﬁne coronary anatomy in patients who developed anginal
symptoms, unstable angina, myocardial infarction (MI) and ischemic
ﬁndings on nonivasive testing.
Coronary intervention
Coronary interventions were performed according to current prac-
tice guidelines and the results were recorded digitally for quantitative
analysis. Degree of coronary stenosis was estimated visually by two
experienced interventional cardiologists.
Deﬁnitions were based on predetermined criteria.
a- ISRwas deﬁned as N50% narrowing of the lumen diameter according
to the results of follow-up coronary angiographies.
b- The Mehran and American College of Cardiology/American Heart
Association classiﬁcations were used to assess lesion shape.8 The
classiﬁcation is based on the length and pattern of the restenotic
lesion in relation to the stented portion of the vessel. Four types
of ISR have been deﬁned: (I) focal (≤10 mm length); (II) diffuse
(ISR N 10 mm within the stent); (III) proliferative (ISR N 10 mm
extending outside the stent); and (IV) occlusive ISR.
c- Target vessel revascularization (TVR) was deﬁned as repeat
percutanous coronary intervention within the index procedure
stent or 5 mm edge.9–10
d- All deaths were considered to be cardiac related unless a clear non-
cardiac cause could be established.
e- The diagnosis of MI required 2 of the following: 1) prolonged
(N30 min) chest pain; 2) a rise in creatine kinase levels exceedingtwice the local upper normal limit value (with abnormal MB
fraction); and 3) development of persistent ischemic electrocardio-
graphic changes (with or without new pathological Q waves).11
f- The Academic Research Consortium deﬁnition was used to assess
the presence of stent thrombosis.12
g- Signiﬁcant coronary stenosis was deﬁned as 50% narrowing of the
lumen diameter in major epicardial coronary vessels.13
All patients received clopidogrel (300 to 600 mg) at least 6 h before
the stent implantation. They also received weight-adjusted intravenous
heparin before the intervention. Procedural success was deﬁned as re-
duction of stenosis to less than 10% residual narrowing, with improve-
ment in ischemic symptoms and without major procedure related
complications: death, emergency bypass surgery, or myocardial
infarction (deﬁned to be greater than twice the increase in creatine
kinase-MB levels).14
Drug eluting sirolimus stent or drug eluting paclitaxel stent was
used instent restenosis. Balloon size was selected in order to achieve
a ﬁnal balloon-to-artery ratio of 1.1/1. Relatively high pressures
(N12 atm) were recommended.
The patients were premedicated with aspirin 100mg/day, and were
given clopidogrel (loading dose of 300 to 600mg) at least 6 h before the
intervention. The patients were advised to stay on clopidogrel for one
year after stent implantation. All patients received optimal medical
therapy.
The decision between BA and DES implantation aswell as the choice
between DES, BA or medical treatment in cases of recurrent restenosis
were left to the operator. Patients in the DES group received DAPT for
one year, whereas patients in the BA received aspirin only.
Intraobserver and interobserver variabilities of ISR analysis were
assessed in a subset of 50 patients. Interpretations of the two investiga-
tors on the presence or absence of ISR agreed in 92% and 95% respective-
ly. Intraobserver variability was assessed by one investigator. The
concordance rate of the two readings for the presence or absence of
ISR was 94% and 95% respectively.
Statistical analysis
Continuous variables are expressed as mean ± SD. Categorical vari-
ables are expressed as percentages. To compare parametric continuous
variables, Student's t-test was used; to compare nonparametric contin-
uous variables, the Mann Whitney U test was used; and to compare
categorical variables, chi-squared test was used. Multivariate logistic
regression analysis was carried out to identify the independent
predictor of MACE. Event-free survival curves were generated by the
Table 1
Patients' clinical characteristics.
BA DES p
Male, n (%) 91 (79.1%) 134 (87%) 0.08
Age, (years) 61.6 ± 11.0 61.7 ± 10.8 0.967
LVEF (%) 64.1 ± 9.3 66.4 ± 8.7 0.63
Current smoker, n (%) 54 (47%) 68 (44.2%) 0.648
Family history of CAD, n (%) 40 (34.7%) 55 (35.6%) 0.40
Diabetes mellitus, n (%) 57 (49.6%) 64 (41.6%) 0.192
Hypertension, n (%) 65 (56.5%) 77 (50%) 0.550
In-hospital medical treatment, n (%)
ACE-I/ARB
Beta blocker
Calcium channel blocker
Statins
47 (41%)
63 (55.1%)
20 (17.4%)
64 (56%)
77 (50%)
91 (59.2%)
26 (17.1%)
83 (54%)
0.645
0.26
0.30
0.13
Fasting glucose, (mg/dL) 101 ± 10 89 ± 11 0.50
HDL-C, (mg/dL) 42 ± 13 44 ± 9.9 0.24
LDL-C, (mg/dL) 140 ± 56 135 ± 28 0.41
Hemoglobin, (g/L) 13.0 ± 1.4 13.3 ± 1.4 0.60
Creatinine, (mg/dL) 0.89 ± 0.27 0.94 ± 0.30 0.08
ACE-I; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blocker, BA;
balloon angioplasty, CAD; coronary artery disease, DES: drug eluting stent, HDL-C; high
density lipoprotein cholesterol, LVEF; left ventricular ejection fraction, LDL-C; low density
lipoprotein cholesterol.
Table 3
1-year follow-up results of the patients.
BA DES p
MACE, n (%) 33 (28.7%) 13 (8.7%) b0.0001
Death, n (%) 15 (13%) 11 (7.1%) 0.105
MI, n (%) 8 (7%) 10 (6.5%) 0.880
Target lesion revascularization, n (%) 23 (20%) 11 (7.1%) 0.002
MACE; major adverse cardiac events, MI; myocardial infarction.
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using log-rank test. All variables showed signiﬁcance values less than
0.05. Two-tailed P values less than 0.05 with a conﬁdence interval of
95% were considered as signiﬁcant. All statistical studies were
performed by using the SPSS program (version 22.0; SPSS Inc., Chicago,
Illinois, USA).Results
Baseline clinical and demographic characteristics were similar in
both groups. There was no difference between the two groups in
terms of age, sex, hypertension, hyperlipidemia, diabetes mellitus,
smoking, LVEF and in-hospital medical treatment. Table 1 shows the
clinical characteristics of the patients.Table 2
Patients' angiographic and procedural characteristics.
BA DES p
Indication for stenting, n (%)
Stable angina pectoris
Unstable angina pectoris
Myocardial infarction
72 (47%)
33 (27%)
10 (8.6%)
91 (59%)
50 (31%)
13 (10%)
0.11
0.23
0.45
Coronary vessel treated, n (%)
LAD
LCX
RCA
Number of treated coronary artery,
n ≥ 2
43 (40.6%)
26 (24.5%)
35(33%)
2 (1.9%)
83 (57.6%)
22 (15.3%)
31 (21.5%)
8 (5.6%)
0.01
Stent length, (mm) 18.9 ± 5.9 16.0 ± 6.6 0.05
Stent diameter, (mm) 2.70 ± 0.54 3.32 ± 0.65 0.04
Lesion morphology of the previous
procedure, n (%)
A
B1
B2
C
15 (13%)
24 (20.8%)
66 (57.4%)
10 (8.6%)
11 (7.1%)
37 (24.2%)
94 (60.9%)
12 (7.8%)
0.723
In-stent restenosis pattern by Mehran
classiﬁcation, n (%)
Pattern I: focal
Pattern II: (diffuse, intrastent)
Pattern III: (proliferative)
Pattern IV: (occlusion)
42 (40.7%)
46 (39.3%)
25 (22.1%)
0 (0%)
64 (33.1%)
51 (32.9%)
20 (13%)
19 (12.3%)
b0.0001
LAD; left anterior descending artery, RCA; right coronary artery; LCX; left circumﬂex
artery.The indications for stenting were similar in both groups. Elapsed
time between stent implantation and ISR intervention was 9.8 ±
9.3 months. There were no statistically signiﬁcant differences between
the two groups in terms of lesion type and stent length. Compared
with BA group, DES group had more LAD lesions involved and larger
stent diameter (Table 2). BAwas used predominantly in class I and II le-
sions, whereas class III and IV lesionswere treatedwithDES. Repeat cor-
onary angiography was performed at 9.3 ± 8.7 and 13.8± 10.5 months
(p = 0.03) in BA and DES groups, respectively. Patients in the BA and
DES groups were followed-up for 51.05± 12.7 and 54.5 ± 13.9 months
(p = 0.147), respectively. Procedural and angiographic variables are
shown in Table 2.
At one-year follow-up, patients in theDES group showed signiﬁcant-
ly lower MACE and TVR. MI and mortality rates were not signiﬁcantly
different between two groups. 1-year follow-up results are given in
Table 3.
A mean of 5 years follow-up resulted in a signiﬁcantly higher com-
posite of MACE including death, MI and TVR, recurrent angina and
TVR in BA group than those in the DES group. Cardiac mortality and
MI rates were similar in both groups. TVR for recurrent restenosis oc-
curred earlier in the BA group than that in the DES-group. Numbers of
repeated target lesion and restenosis rate were both higher for the BA
group than for theDES group. The incidence of deﬁnite stent thrombosis
was similar in both groups. Of all six patients with stent thrombosis,
four had stopped antiplatelet therapy prior to elective surgery and
only two patients were on DAPT. Five-year follow-up results are given
in Table 4.
Fig. 2 shows the 5-year event-free survival of the patients. MACE-free
1-year survival and 5-year survival rates were signiﬁcantly higher in DES
group compared to BA group. There was a progressive decrease in LVEF
and renal function in BA group compared to DES group. However, these
differences were not statistically signiﬁcant.
Table 5 shows the results of the multivariate analysis to identify the
predictors of MACE. Diabetes, lesion type, treatment device (BA or DES)Table 4
5-year follow-up results of the patients.
BA DES p
Follow-up duration, years 4.21 ± 1.03 4.49 ± 1.13 0.043
Composite MACE, n (%) 58 (50.4%) 49 (31.8%) 0.002
Cardiac death, n (%) 25 (21.7%) 25 (16.2%) 0.251
CABG surgery, n (%) 5 (4.3%) 6 (3.9%) 0.380
MI, n (%) 7 (6.1%) 8 (5.2%) 0.752
Recurrent angina, n (%) 49 (42.6%) 42 (27.3%) 0.009
Time to repeat revascularization
months, n (%)
8.7 ± 4.2 12.5 ± 4.4 0.02
Target lesion revascularization, n (%) 43 (37.4%) 32 (20.8%) 0.003
Repeated target lesion, n 2.0 ± 0.8 1.38 ± 0.5 0.01
Stent thrombosis, n (%) 1 (0.9%) 6 (3.9%) 0.123
Acute, n (%) 1 (0.9%) 1 (0.6%)
Subacute, n (%) 0 (0%) 1 (0.6%)
Late, n (%) 0 (0%) 4 (2.5%)
New lesion stenting, n (%) 8 (7%) 9 (%5.8) 0.711
Cardiac event free survival, n (%) 57 (49.6%) 105 (68.2%) b0.0001
Restenosis rate 44 (38.3%) 33 (21.4%) 0.003
CABG surgery; coronary artery bypass graft surgery, MACE; major adverse cardiac events,
MI; myocardial infarction.
Fig. 2. Kaplan–Meier analysis of the event-free survival at ﬁve years according to
treatment group.
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multivariate analysis.Discussion
Themain ﬁnding of our studywas that, at 5-year follow-up, compos-
iteMACE, recurrent angina and TVRwere signiﬁcantly lower andMACE-
free survival was signiﬁcantly better in the DES treated patients.
However mortality and risk of MI did not differ between two groups.
DES use was associated with lower rates of composite MACE and TVR,
although it was utilized in patients with more complicated lesions.
Coronary stent implantation is frequently performed in percutanous
coronary interventions. ISR is a major late complication following BMS
implantation, which occurs in 10–80% of lesions treated in daily
practice.8 BMS-ISR is an independent predictor of mortality.15,16 The
use of BMS is associated with high restenosis rate (up to 25%). Although
DES dramatically reduced the rate of restenosis to less than 10%,17,18 it is
associated with increased risk for late stent thrombosis and requires
prolonged DAPT.19
Any percutaneous coronary intervention causes trauma to the vessel
wall. ISR is generally viewed as a healing response after injury incurred
during stent placement. This is characterized by a sequence of inﬂam-
mation, granulation, extracellular matrix remodeling and smooth mus-
cle cell proliferation. These processes lead to neointimal hyperplasia.
Predictive factors of restenosis can be classiﬁed into patient-related,
lesion-related and procedure-related factors. Lesion-related factors
can be listed as vessel diameter, tortuous vessels, calciﬁed lesions andTable 5
Multivariate predictors of composite MACE.
OR %95 CI p
HT 1.24 0.73–2.11 0.417
DM 0.466 0.291–0.843 0.003
Number of diseased coronary arteries 1.13 0.69–1.84 0.624
Lesion type 0.66 0.001
Stent length (mm) 0.993 0.948–1.04 0.779
Mehran classiﬁcation 2.82 2.09–3.89 0.000
Number of stents used 0.789 0.505–1.23 0.300
Stent diameter 0.684 0.312–1.49 0.341
Treatment with BA or DES 2.18 1.32–3.59 0.002
BA, balloon angioplasty, CI; conﬁdence interval, DES; drug eluting stent, DM; diabetes
mellitus, HT; hypertension, OR; odds ratio.previous restenosis. Patient-related factors include patient age, diabetes
mellitus and genetic factors. Procedural characteristics predicting ISR
are residual dissection and length of stented segment.20
Several therapeutic options to treat ISR have been proposed, such as
repeat BA, repeat stenting, cutting balloon angioplasty, directional coro-
nary atherectomy, rotational coronary atherectomy, brachytherapy,
DES, molecular biology and genetics. BA has been used frequently, as
it is relatively inexpensive and easy to perform. DES have achieved
great success in treating patients with de-novo lesions. These ﬁndings
provide a hope for the treatment of ISR. Sirolimus and paclitaxel inhibit
smooth muscle cell proliferation andmigration in vitro and in vivo.21,22
Several studies have demonstrated that stents eluting sirolimus
(Cypher, Cordis a Johnson and Johnson Company) and paclitaxel
(TAXUS NIRx, Boston Scientiﬁc Corporation) reduce ISR.23–27 It has
been shown that oral therapy with sirolimus before and after repeat
intervention results in a signiﬁcant improvement in the angiographic
parameters of restenosis.28 Paclitaxel-coated balloon catheters reduce
repeat restenosis in patients with ISR.29
In spite of insufﬁcient data, interventional cardiologists commonly
use the stent sandwich technique to treat ISR. Final lumen cross-
sectional area is the independent predictor of subsequent ISR and TVR.
Full stent expansion with sufﬁcient lumen area (lumen area 90% or
greater of the average reference lumen area preintervention)minimizes
restenosis. Compared to BA, coronary stenting achieved better initial
angiographic results but fails to improve restenosis rate in patients
with ISR. However, patients with large vessels (≥3 mm) have a better
outcome after repeat stenting.4
ISAR-DESIRE study randomized 300 patients with BMS ISR to treat-
ment with SES, PES and BA.30 At 1-year follow-up, the use of DES led
to signiﬁcantly lower rates of TVR. DES were markedly superior to con-
ventional balloon angioplasty for the treatment of BMS-ISR. RIBS-II
compares the results of SES with those of BMS in patients with ISR.11
At 1 year, the event-free survival was better in the SES group. At
4 years, the event-free survival was 76% in the SES arm and 65% in the
BA arm (p= 0.019). Same researchers published the results of 450 pa-
tients with ISR treated with BA or repeat BMS implantation.4 In that
study, binary restenosis rate, TVR and one-year event-free survival
were similar in both groups.
In our study, MACE and TVR rates were consistent with other stud-
ies. Myocardial and cardiac deaths were similar in both groups. During
follow-up MACE rates were signiﬁcantly lower and MACE-free survival
was signiﬁcantly better in the DES treated patients.Conclusions
ISR has been a longstanding problem after percutaneous coronary
intervention. The pathophysiology of ISR is multifactorial. There are
several options for therapy and treatments that should therefore be
individualized. Although DES have signiﬁcantly reduced in-hospital
complications, ISR and TVR, BA compared with DES resulted in similar
rates of mortality and MI. Hence, BA may be the preferred method of
treatment. Recent advances in DES technology have allowed cardiolo-
gists to treat much more complicated lesions and have dramatically
reduced the rates of ISR and TVR.Study limitations
Our study has several limitations. It was a retrospective analysis of
data at a single center and the number of patients was small. Discontin-
uation of medical treatment during follow-up may affect the patient
outcomes. Decision between BA and DES implantation was left up to
the operator. Another limitation was that the current funding restric-
tions in our country affected the operator preferences and resulted in
lower DES use.
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